[Pathogenic substances in Parkinson disease and new therapeutics considering the etiologic mechanism].
Nagatsu
T
T
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D001708:Biopterins / Q000031:analogs & derivatives / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use*; D015103:Droxidopa / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D009417:Nerve Tissue / Q000637:transplantation; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D011725:Pyridines / Q000096:biosynthesis; D012694:Serine / Q000031:analogs & derivatives*
D015259:Dopamine Agents; D011725:Pyridines; D001708:Biopterins; D012694:Serine; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; C003402:sapropterin; D015103:Droxidopa